留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

我国诊疗一体化核素及放射性药物临床应用与展望

陈跃

陈跃. 我国诊疗一体化核素及放射性药物临床应用与展望[J]. 协和医学杂志, 2022, 13(2): 187-191. doi: 10.12290/xhyxzz.2021-0557
引用本文: 陈跃. 我国诊疗一体化核素及放射性药物临床应用与展望[J]. 协和医学杂志, 2022, 13(2): 187-191. doi: 10.12290/xhyxzz.2021-0557
CHEN Yue. Development and Prospect of Theranostic Medical Isotopes and Radiopharmaceuticals in China[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 187-191. doi: 10.12290/xhyxzz.2021-0557
Citation: CHEN Yue. Development and Prospect of Theranostic Medical Isotopes and Radiopharmaceuticals in China[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 187-191. doi: 10.12290/xhyxzz.2021-0557

我国诊疗一体化核素及放射性药物临床应用与展望

doi: 10.12290/xhyxzz.2021-0557
基金项目: 

国家自然科学基金 U20A20384

详细信息
    通讯作者:

    陈跃,E-mail:chenyue5523@126.com

  • 中图分类号: R445; R-1

Development and Prospect of Theranostic Medical Isotopes and Radiopharmaceuticals in China

Funds: 

National Natural Science Foundation of China U20A20384

More Information
  • 摘要: 核医学诊疗一体化是将放射性核素显像与内放射治疗相结合,从而实现疾病的可视化诊断和精准治疗。目前,核医学诊疗一体化已在分化型甲状腺癌、嗜铬细胞瘤、恶性肿瘤骨转移、神经内分泌肿瘤、前列腺癌中发挥重要作用。我国医用放射性核素及放射性药物短缺,严重依赖进口,存在“卡脖子”问题,应加强诊疗一体化医用放射性核素及放射性药物的自主生产与创新研发力度,以促进核医学诊疗一体化更好地服务我国临床实践。
    利益冲突:作者声明不存在利益冲突
  • 图  1  诊疗一体化放射性药物示意图

    表  1  常用诊疗一体化放射性药物及临床应用[3-4]

    诊断性放射性药物 治疗性放射性药物 临床诊断与治疗病种
    Na123I、Na124I Na131I 分化型甲状腺癌
    123I-MIBG、124I-MIBG 131I-MIBG 嗜铬细胞瘤
    99mTc-MDP、18F-NaF 89SrCl2223RaCl2 恶性肿瘤骨转移
    68Ga-DOTATATE 177Lu-DOTATATE 神经内分泌肿瘤
    68Ga-PSMA 177Lu-PSMA 前列腺癌
    下载: 导出CSV

    表  2  具有应用前景的诊疗一体化核素

    诊断性放射性核素 配对的治疗性放射性核素
    123I/124I 131I
    68Ga 177Lu
    68Ga 225Ac
    64Gu 67Gu
    44Sc 47Sc
    152Tb 161Tb
    86Y 90Y
    99mTc 188Re
    下载: 导出CSV
  • [1] Filippi L, Chiaravalloti A, Schillaci O, et al. Theranostic approaches in nuclear medicine: current status and future prospects[J]. Expert Rev Med Devices, 2020, 17: 331-343. doi:  10.1080/17434440.2020.1741348
    [2] Jokar N, Assadi M, Yordanova A, et al. Bench-to-Bedside Theranostics in Nuclear Medicine[J]. Curr Pharm Des, 2020, 26: 3804-3811. doi:  10.2174/1381612826666200218104313
    [3] Solnes LB, Shokeen M, Pandit-Taskar N. Novel Agents and Future Perspectives on Theranostics[J]. Semin Radiat Oncol, 2021, 31: 83-92. doi:  10.1016/j.semradonc.2020.07.010
    [4] O'Dwyer E, Bodei L, Morris MJ. The Role of Theranostics in Prostate Cancer[J]. Semin Radiat Oncol, 2021, 31: 71-82. doi:  10.1016/j.semradonc.2020.07.004
    [5] 张锦明, 杜进. 中国放射性药物制备的现状及展望[J]. 同位素, 2019, 32: 178-185. doi:  10.7538/tws.2019.32.03.0178

    Zhang JM, Du J. Preparation of Radiopharmaceuticals in China: Current Status and Prospects[J]. Tongweisu, 2019, 32: 178-185. doi:  10.7538/tws.2019.32.03.0178
    [6] Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1588-1601. doi:  10.1007/s00259-017-3728-y
    [7] Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi:  10.1056/NEJMoa1607427
    [8] Ali N, Sebastian C, Foley RR, et al. The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy[J]. Nucl Med Commun, 2006, 27: 165-169. doi:  10.1097/01.mnm.0000194397.20067.b6
    [9] Nagarajah J, Janssen M, Hetkamp P, et al. Iodine Symporter Targeting with 124I/131I Theranostics[J]. J Nucl Med, 2017, 58: 34S-38S. doi:  10.2967/jnumed.116.186866
    [10] Gulec SA, Kuker RA, Goryawala M, et al. 124I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis[J]. Thyroid, 2016, 26: 441-448. doi:  10.1089/thy.2015.0482
    [11] Furuta N, Kiyota H, Yoshigoe F, et al. Diagnosis of pheochromocytoma using[123I]-compared with[131I]-metaiodobenzylguanidine scintigraphy[J]. Int J Urol, 1999, 6: 119-124. doi:  10.1046/j.1442-2042.1999.06310.x
    [12] Pryma DA, Chin BB, Noto RB, et al. Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma[J]. J Nucl Med, 2019, 60: 623-630. doi:  10.2967/jnumed.118.217463
    [13] Willegaignon J, Crema KP, Oliveira NC, et al. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures[J]. Clin Nucl Med, 2018, 43: 572-578. doi:  10.1097/RLU.0000000000002158
    [14] Weber M, Schmitz J, Maric I, et al. Diagnostic performance of 124I-m-iodobenzylguanidine PET/CT in patients with pheochromocytoma[J]. J Nucl Med, 2021. doi:  10.2967/jnumed.121.262797.
    [15] 支修益, 石远凯, 于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志, 2015, 37: 67-78. doi:  10.3760/cma.j.issn.0253-3766.2015.01.014

    Zhi XY, Shi YK, Yu JM. Standards for the diagnosis and treatment of primary lung cancer(2015 version) in China[J]. Zhonghua Zhongliu Zazhi, 2015, 37: 67-78. doi:  10.3760/cma.j.issn.0253-3766.2015.01.014
    [16] 陈跃, 赵军, 吴湖炳, 等. 18F-NaF PET/CT骨显像操作指南[J]. 中华核医学与分子影像杂志, 2016, 36: 76-78. doi:  10.3760/cma.j.issn.2095-2848.2016.01.018

    Chen Y, Zhao J, Wu HB, et al. Operation guide of 18F-NaF PET/CT bone imaging[J]. Zhonghua Heyixue Yu Fenzi Yingxiang Zazhi, 2016, 36: 76-78. doi:  10.3760/cma.j.issn.2095-2848.2016.01.018
    [17] Handkiewicz-Junak D, Poeppel TD, Bodei L, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 846-859. doi:  10.1007/s00259-018-3947-x
    [18] Manafi-Farid R, Masoumi F, Divband G, et al. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain[J]. J Clin Med, 2020, 9: 2622. doi:  10.3390/jcm9082622
    [19] Sadremomtaz A, Masoumi M. Comparison between Targeted Radionuclide Therapy of Bone Metastases Based on β-Emitting and α-Emitting Radionuclides[J]. J Med Imaging Radiat Sci, 2019, 50: 272-279. doi:  10.1016/j.jmir.2018.12.005
    [20] Sanli Y, Garg I, Kandathil A, et al. Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT[J]. AJR Am J Roentgenol, 2018, 211: 267-277. doi:  10.2214/AJR.18.19881
    [21] 陈跃, 霍力, 兰晓莉, 等. 68Ga-DOTA-生长抑素受体PET/CT神经内分泌肿瘤显像操作指南[J]. 中国医学影像技术, 2019, 35: 1441-1444. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201909001.htm

    Chen Y, Huo L, Lan XL, et al. Guideline of 68Ga-DOTA-conjugated somatostatin receptor PET/CT imaging in neuroendocrine neoplasms[J]. Zhongguo Yixue Yingxiang Jishu, 2019, 35: 1441-1444. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201909001.htm
    [22] Zhang J, Song Q, Cai L, et al. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 2020, 146: 1533-1543. doi:  10.1007/s00432-020-03181-2
    [23] Farolfi A, Lima GM, Oyen W, et al. Molecular Imaging and Theranostics-A Multidisciplinary Approach[J]. Semin Nucl Med, 2019, 49: 247-254. doi:  10.1053/j.semnuclmed.2019.02.002
    [24] Hamed M, Basha M, Ahmed H, et al. 68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy[J]. Acad Radiol, 2019, 26: 450-460. doi:  10.1016/j.acra.2018.05.020
    [25] 陈跃, 霍力, 兰晓莉, 等. 68Ga-前列腺特异性膜抗原PET/CT前列腺癌显像操作指南[J]. 中国医学影像技术, 2019, 35: 1281-1284. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201910001.htm

    Chen Y, Huo L, Lan XL, et al. Guideline of 68Ga-PSMA PET/CT imaging in prostatic cancer[J]. Zhongguo Yixue Yingxiang Jishu, 2019, 35: 1281-1284. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201910001.htm
    [26] Yadav MP, Ballal S, Sahoo RK, et al. Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis[J]. AJR Am J Roentgenol, 2019, 213: 275-285. doi:  10.2214/AJR.18.20845
    [27] Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 2536-2544. doi:  10.1007/s00259-019-04485-3
    [28] Yadav MP, Ballal S, Sahoo RK, et al. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients[J]. Theranostics, 2020, 10: 9364-9377. doi:  10.7150/thno.48107
    [29] Goldsmith SJ. Targeted Radionuclide Therapy: A Historical and Personal Review[J]. Semin Nucl Med, 2020, 50: 87-97. doi:  10.1053/j.semnuclmed.2019.07.006
    [30] Jokar N, Velikyan I, Ahmadzadehfar H, et al. Theranostic Approach in Breast Cancer: A Treasured Tailor for Future Oncology[J]. Clin Nucl Med, 2021, 46: e410-e420. doi:  10.1097/RLU.0000000000003678
    [31] Jadvar H. Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies[J]. Cancer Biother Radiopharm, 2020, 35: 475-484. doi:  10.1089/cbr.2019.3340
    [32] Brito AE, Etchebehere E. Radium-223 as an Approved Modality for Treatment of Bone Metastases[J]. Semin Nucl Med, 2020, 50: 177-192. doi:  10.1053/j.semnuclmed.2019.11.005
    [33] Frantellizzi V, Cosma L, Brunotti G, et al. Targeted Alpha Therapy with Thorium-227[J]. Cancer Biother Radiopharm, 2020, 35: 437-445. doi:  10.1089/cbr.2019.3105
    [34] Anand A, Trägårdh E, Edenbrandt L, et al. Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients[J]. J Nucl Med, 2020, 61: 671-675. doi:  10.2967/jnumed.119.231100
  • 加载中
图(1) / 表(2)
计量
  • 文章访问数:  329
  • HTML全文浏览量:  31
  • PDF下载量:  139
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-07-26
  • 录用日期:  2021-11-22
  • 网络出版日期:  2021-11-23
  • 刊出日期:  2022-03-30

目录

    /

    返回文章
    返回